相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Intermittent convection-enhanced delivery of GDNF into rhesus monkey putamen: absence of local or cerebellar toxicity
Matthias Luz et al.
ARCHIVES OF TOXICOLOGY (2018)
Alpha-Synuclein mRNA Is Not Increased in Sporadic PD and Alpha-Synuclein Accumulation Does Not Block GDNF Signaling in Parkinson's Disease and Disease Models
Xiaomin Su et al.
MOLECULAR THERAPY (2017)
Robust graft survival and normalized dopaminergic innervation do not obligate recovery in a Parkinson disease patient
Jeffrey H. Kordower et al.
ANNALS OF NEUROLOGY (2017)
Striatal dopamine in Parkinson disease: A meta-analysis of imaging studies
Valtteri Kaasinen et al.
ANNALS OF NEUROLOGY (2017)
Chronic, intermittent convection-enhanced delivery devices
Owen Lewis et al.
JOURNAL OF NEUROSCIENCE METHODS (2016)
A novel implantable catheter system with transcutaneous port for intermittent convection-enhanced delivery of carboplatin for recurrent glioblastoma
Neil U. Barua et al.
DRUG DELIVERY (2016)
Disease duration and the integrity of the nigrostriatal system in Parkinson's disease
Jeffrey H. Kordower et al.
BRAIN (2013)
In vitro and in vivo testing of a novel recessed-step catheter for reflux-free convection-enhanced drug delivery to the brain
T. Gill et al.
JOURNAL OF NEUROSCIENCE METHODS (2013)
Intermittent convection-enhanced delivery to the brain through a novel transcutaneous bone-anchored port
N. U. Barua et al.
JOURNAL OF NEUROSCIENCE METHODS (2013)
BENEFITS OF PUTAMINAL GDNF INFUSION IN PARKINSON DISEASE ARE MAINTAINED AFTER GDNF CESSATION
Nikunj K. Patel et al.
NEUROLOGY (2013)
GDNF, NGF and BDNF as therapeutic options for neurodegeneration
Shelley J. Allen et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Long-Term Evaluation of a Phase 1 Study of AADC Gene Therapy for Parkinson's Disease
Gabriele Mittermeyer et al.
HUMAN GENE THERAPY (2012)
The development of an implantable catheter system for chronic or intermittent convection-enhanced delivery
A. Bienemann et al.
JOURNAL OF NEUROSCIENCE METHODS (2012)
α-Synuclein-Induced Down-Regulation of Nurr1 Disrupts GDNF Signaling in Nigral Dopamine Neurons
Mickael Decressac et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease
Mickael Decressac et al.
BRAIN (2011)
Milestones in Parkinson's Disease Therapeutics
Olivier Rascol et al.
MOVEMENT DISORDERS (2011)
Image-guided convection-enhanced delivery of GDNF protein into monkey putamen
Francisco Gimenez et al.
NEUROIMAGE (2011)
Neuroimaging in Parkinson's Disease
A. Jon Stoessl
NEUROTHERAPEUTICS (2011)
The Clinically Important Difference on the Unified Parkinson's Disease Rating Scale
Lisa M. Shulman et al.
ARCHIVES OF NEUROLOGY (2010)
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial
William J. Marks et al.
LANCET NEUROLOGY (2010)
Pharmacokinetics and bioactivity of glial cell line-derived factor (GDNF) and neurturin (NTN) infused into the rat brain
Piotr Hadaczek et al.
NEUROPHARMACOLOGY (2010)
Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study
R. Nandhagopal et al.
BRAIN (2009)
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial
William J. Marks et al.
LANCET NEUROLOGY (2008)
Placebo response in Parkinson's disease: Comparisons among 11 trials covering medical and surgical interventions
Christopher G. Goetz et al.
MOVEMENT DISORDERS (2008)
Point source concentration of GDNF may explain failure of phase II clinical trial
Michael F. Salvatore et al.
EXPERIMENTAL NEUROLOGY (2006)
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease
AE Lang et al.
ANNALS OF NEUROLOGY (2006)
Epidemiology of Parkinson's disease
Lonneke M. L. de Lau et al.
LANCET NEUROLOGY (2006)
Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain
S Love et al.
NATURE MEDICINE (2005)
Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor
JT Slevin et al.
JOURNAL OF NEUROSURGERY (2005)
A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease
CW Olanow et al.
ANNALS OF NEUROLOGY (2003)
Monoamine neuron innervation of the normal human brain:: an 18F-DOPA PET study
RY Moore et al.
BRAIN RESEARCH (2003)
Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue
V Cochen et al.
MOVEMENT DISORDERS (2003)
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study
AL Whone et al.
ANNALS OF NEUROLOGY (2003)
Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease
SS Gill et al.
NATURE MEDICINE (2003)
Effect of dopamine loss and the metabolite 3-O-methyl-[18F]fluoro-dopa on the relation between the 18F-fluorodopa tissue input uptake rate constant Kocc and the [18F]fluorodopa plasma input uptake rate constant Ki
V Sossi et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2003)
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD
JG Nutt et al.
NEUROLOGY (2003)
Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys
R Grondin et al.
BRAIN (2002)
The GDNF family: Signalling, biological functions and therapeutic value
MS Airaksinen et al.
NATURE REVIEWS NEUROSCIENCE (2002)
Inhibition of brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor expression reduces dopaminergic sprouting in the injured striatum
PE Batchelor et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2000)
The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages
M Aoi et al.
NEUROSCIENCE RESEARCH (2000)
分享论文
